Table 1. Baseline characteristics for third dose cohort.
| Baseline characteristics | n=106 |
|---|---|
| Age (median, IQR) | 68 (63.25–76.5) |
| Sex | |
| Male | 48 (45%) |
| Female | 58 (55%) |
| Race | |
| Caucasian | 36 (34%) |
| African-American | 33 (31%) |
| Hispanic | 27 (25%) |
| Asian | 9 (8%) |
| Other | 1 (1%) |
| Previous vaccine given | |
| BNT162b2 | 72 (68%) |
| mRNA-1273 | 28 (26%) |
| Ad26.CoV2.S | 6 (6%) |
| Type of booster vaccine | |
| BNT162b2 | 78 (74%) |
| mRNA-1273 | 28 (26%) |
| Malignancy category | |
| Hematologic malignancy | 66 (62%) |
| Solid Malignancy | 40 (38%) |
| Lymphoid/myeloid/solid | |
| Lymphoid | 55 (52%) |
| Myeloid | 11 (10%) |
| Solid | 40 (38%) |
| Cancer status | |
| Active | 69 (65%) |
| Progressive | 3 (3%) |
| Recurrent | 3 (3%) |
| Relapse | 7 (7%) |
| Remission | 24 (23%) |
| On treatment at the time of booster | |
| Yes | 80 (75%) |
| No | 26 (25%) |